27 pending office actions • 2 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Regeneron Pharmaceuticals, Inc. | 26 |
| Regeneron Pharmaceuticals, Inc. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18582159 | Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR) | Regeneron Pharmaceuticals, Inc. | KAPUSHOC, STEPHEN THOMAS | 1683 | Non-Final OA | Feb 20, 2024 |
| 18488316 | HSD17B13 VARIANTS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. | ZAHORIK, AMANDA MARY | 1636 | Non-Final OA | Oct 17, 2023 |
| 18485592 | Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors | Regeneron Pharmaceuticals, Inc. | WHITEMAN, BRIAN A | 1636 | Non-Final OA | Oct 12, 2023 |
| 18244577 | Treatment Of Endometriosis With R-Spondin 3 (RSPO3) Inhibitors | Regeneron Pharmaceuticals, Inc. | TATGE, LEXUS MARC | 1637 | Non-Final OA | Sep 11, 2023 |
| 18355108 | Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses Thereof | Regeneron Pharmaceuticals, Inc. | SCHWECHTER, BRANDON ROSS | 1674 | Non-Final OA | Jul 19, 2023 |
| 18306737 | Transcriptome Analysis For Treating Inflammation | Regeneron Pharmaceuticals, Inc. | SMITH, EMILIE ALINE | 1686 | Non-Final OA | Apr 25, 2023 |
| 18110130 | SEQUENCE VARIANT ANALYSIS USING HEAVY PEPTIDES | Regeneron Pharmaceuticals, Inc. | ALABI, OYELEYE A | 1797 | Non-Final OA | Feb 15, 2023 |
| 18157587 | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | Regeneron Pharmaceuticals, Inc. | CASH, KAILEY ELIZABETH | 1683 | Non-Final OA | Jan 20, 2023 |
| 18152346 | Triggering Receptor Expressed On Myeloid Cells 2 (TREM2) Variants And Uses Thereof | Regeneron Pharmaceuticals, Inc. | SALMON, KATHERINE D | 1682 | Non-Final OA | Jan 10, 2023 |
| 18067982 | Methods Of Identifying And Evaluating Liver Inflammation And Liver Fibrosis In A Subject By Determining A Stratified Score Based On Gene Expression | Regeneron Pharmaceuticals, Inc. | BICKHAM, DAWN MARIE | 1685 | Non-Final OA | Dec 19, 2022 |
| 18067085 | Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) Inhibitors | Regeneron Pharmaceuticals, Inc. | PAK, MICHAEL D | 1674 | Non-Final OA | Dec 16, 2022 |
| 18059719 | Treatment Of Lung Disease Based Upon Stratification Of Polygenic Score Relating To Response To A Therapeutic Agent | Regeneron Pharmaceuticals, Inc. | GODDARD, LAURA B | 1642 | Final Rejection | Nov 29, 2022 |
| 18057298 | Methods Of Treating Headaches And Migraines With Sodium Voltage-Gated Channel Alpha Subunit 11 (SCN11A) Inhibitors | Regeneron Pharmaceuticals, Inc. | TATGE, LEXUS MARC | 1637 | Non-Final OA | Nov 21, 2022 |
| 18051488 | Association Of T Cell Leukemia/Lymphoma Protein 1A (TCL1A) With Clonal Hematopoiesis Of Indeterminate Potential (CHIP) | Regeneron Pharmaceuticals, Inc. | KAPUSHOC, STEPHEN THOMAS | 1683 | Non-Final OA | Oct 31, 2022 |
| 17936715 | Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors | Regeneron Pharmaceuticals, Inc. | ANGELL, JON E | 1637 | Non-Final OA | Sep 29, 2022 |
| 17934277 | Methods Of Treating Chronic Kidney Disease (CKD) With Inhibitors Of Protective Loss-Of-Function Genes | Regeneron Pharmaceuticals, Inc. | KENYON, JOHN S | 1625 | Non-Final OA | Sep 22, 2022 |
| 17931396 | Methods Of Treating Clonal Hematopoiesis Of Indeterminate Potential (CHIP) With Lymphocyte Antigen 75 (LY75), Cluster Of Differentiation 164 (CD164), Or Poly(ADP-Ribose) Polymerase 1 (PARP1) Inhibitors | Regeneron Pharmaceuticals, Inc. | DARPOLOR, JOSEPHINE KEBBEH | 1642 | Final Rejection | Sep 12, 2022 |
| 17821806 | Treatment Of Inflammatory Diseases With RAS Protein Activator Like 3 (RASAL3) Inhibitors | Regeneron Pharmaceuticals, Inc. | VYAS, KEYUR ANILKUMAR | 1637 | Final Rejection | Aug 24, 2022 |
| 17810820 | Treatment of Varicose Veins With Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) Agonists | Regeneron Pharmaceuticals, Inc. | MYERS, CARLA J | 1682 | Final Rejection | Jul 05, 2022 |
| 17854412 | Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) Inhibitors | Regeneron Pharmaceuticals, Inc. | KAPUSHOC, STEPHEN THOMAS | 1683 | Final Rejection | Jun 30, 2022 |
| 17854283 | Methods Of Treating Asthma With Solute Carrier Family 27 Member 3 (SLC27A3) Inhibitors | Regeneron Pharmaceuticals, Inc. | KAPUSHOC, STEPHEN THOMAS | 1683 | Final Rejection | Jun 30, 2022 |
| 17855053 | Methods Of Treating Decreased Bone Mineral Density With Kringle Containing Transmembrane Protein 1 (KREMEN1) Inhibitors | Regeneron Pharmaceuticals, Inc. | POLIAKOVA-GEORGAN, EKATERINA | 1637 | Non-Final OA | Jun 30, 2022 |
| 17683468 | Treatment Of Liver Disease With Ring Finger Protein 213 (RNF213) Inhibitors | Regeneron Pharmaceuticals, Inc. | VYAS, KEYUR ANILKUMAR | 1637 | Non-Final OA | Mar 01, 2022 |
| 17584642 | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | Regeneron Pharmaceuticals, Inc. | SUNSHINE, HANNAH LOUISE | 1647 | Non-Final OA | Jan 26, 2022 |
| 17443702 | Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) Inhibitors | Regeneron Pharmaceuticals, Inc. | HUDSON, AMY ROSE | 1636 | Final Rejection | Jul 27, 2021 |
| 17204636 | METHODS AND SYSTEMS FOR DETERMINING RESPONDERS TO TREATMENT | Regeneron Pharmaceuticals, Inc. | AUGER, NOAH ANDREW | 1687 | Final Rejection | Mar 17, 2021 |
| 17091484 | Accurate And Robust Information-Deconvolution From Bulk Tissue Transcriptomes | Regeneron Pharmaceuticals, Inc. | STRIEGEL, THEODORE CHARLES | 1685 | Final Rejection | Nov 06, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial